JP2018504094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504094A5 JP2018504094A5 JP2017529750A JP2017529750A JP2018504094A5 JP 2018504094 A5 JP2018504094 A5 JP 2018504094A5 JP 2017529750 A JP2017529750 A JP 2017529750A JP 2017529750 A JP2017529750 A JP 2017529750A JP 2018504094 A5 JP2018504094 A5 JP 2018504094A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- chain variable
- variable region
- binding domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 173
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 158
- 239000000427 antigen Substances 0.000 claims description 150
- 102000036639 antigens Human genes 0.000 claims description 150
- 108091007433 antigens Proteins 0.000 claims description 150
- 230000004048 modification Effects 0.000 claims description 112
- 238000012986 modification Methods 0.000 claims description 112
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 76
- 229920001184 polypeptide Polymers 0.000 claims description 72
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 72
- 150000001413 amino acids Chemical class 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 54
- 150000007523 nucleic acids Chemical class 0.000 claims description 48
- 230000028993 immune response Effects 0.000 claims description 37
- 206010028980 Neoplasm Diseases 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 28
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 22
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 22
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 16
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 16
- 208000034578 Multiple myelomas Diseases 0.000 claims description 16
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 16
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 16
- 230000000139 costimulatory effect Effects 0.000 claims description 16
- 230000011664 signaling Effects 0.000 claims description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 14
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 14
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 14
- 230000003834 intracellular effect Effects 0.000 claims description 12
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 8
- 208000017604 Hodgkin disease Diseases 0.000 claims description 8
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 8
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 8
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 6
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 6
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 201000000564 macroglobulinemia Diseases 0.000 claims description 6
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 2
- 108010083359 Antigen Receptors Proteins 0.000 claims description 2
- 102000006306 Antigen Receptors Human genes 0.000 claims description 2
- 102100036008 CD48 antigen Human genes 0.000 claims description 2
- 102100025221 CD70 antigen Human genes 0.000 claims description 2
- -1 CD86 Proteins 0.000 claims description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 claims description 2
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 claims description 2
- 108090000177 Interleukin-11 Proteins 0.000 claims description 2
- 108010065805 Interleukin-12 Proteins 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108050003558 Interleukin-17 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010002386 Interleukin-3 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 108010042215 OX40 Ligand Proteins 0.000 claims description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 2
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 claims description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- 230000036039 immunity Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022029515A JP2022066290A (ja) | 2014-12-05 | 2022-02-28 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2024019513A JP2024040376A (ja) | 2014-12-05 | 2024-02-13 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462088164P | 2014-12-05 | 2014-12-05 | |
| US62/088,164 | 2014-12-05 | ||
| PCT/US2015/064134 WO2016090337A1 (en) | 2014-12-05 | 2015-12-04 | Chimeric antigen receptors targeting fc receptor-like 5 and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022029515A Division JP2022066290A (ja) | 2014-12-05 | 2022-02-28 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504094A JP2018504094A (ja) | 2018-02-15 |
| JP2018504094A5 true JP2018504094A5 (Direct) | 2019-01-17 |
| JP7174522B2 JP7174522B2 (ja) | 2022-11-17 |
Family
ID=56092578
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529750A Active JP7174522B2 (ja) | 2014-12-05 | 2015-12-04 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2022029515A Withdrawn JP2022066290A (ja) | 2014-12-05 | 2022-02-28 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2024019513A Pending JP2024040376A (ja) | 2014-12-05 | 2024-02-13 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022029515A Withdrawn JP2022066290A (ja) | 2014-12-05 | 2022-02-28 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
| JP2024019513A Pending JP2024040376A (ja) | 2014-12-05 | 2024-02-13 | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11059891B2 (Direct) |
| EP (2) | EP4506036A3 (Direct) |
| JP (3) | JP7174522B2 (Direct) |
| KR (1) | KR20170108946A (Direct) |
| CN (2) | CN109072199B (Direct) |
| AU (2) | AU2015357543B2 (Direct) |
| BR (1) | BR112017011936A8 (Direct) |
| IL (2) | IL252655B (Direct) |
| MX (1) | MX395028B (Direct) |
| MY (1) | MY192062A (Direct) |
| NZ (1) | NZ732570A (Direct) |
| PH (1) | PH12017501041A1 (Direct) |
| SG (2) | SG10202008076RA (Direct) |
| WO (1) | WO2016090337A1 (Direct) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109072199B (zh) | 2014-12-05 | 2022-10-28 | 纪念斯隆-凯特琳癌症中心 | 靶向Fc受体样5的嵌合抗原受体及其用途 |
| TWI773647B (zh) * | 2015-06-23 | 2022-08-11 | 史隆凱特林紀念癌症中心 | 新穎pd-1免疫調控劑 |
| MY197441A (en) | 2015-12-04 | 2023-06-19 | Memorial Sloan Kettering Cancer Center | Antibodies targeting fc receptor-like 5 and method of use |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| JP2020517287A (ja) | 2017-04-26 | 2020-06-18 | ユーリカ セラピューティックス， インコーポレイテッド | キメラ抗体／ｔ細胞受容体構築物及びその使用 |
| EP3687569A1 (en) | 2017-09-29 | 2020-08-05 | Cell Design Labs, Inc. | Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same |
| US11866785B2 (en) | 2017-10-27 | 2024-01-09 | Board Of Regents, The University Of Texas System | Tumor specific antibodies and T-cell receptors and methods of identifying the same |
| US20200371091A1 (en) | 2017-11-30 | 2020-11-26 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| KR102452246B1 (ko) | 2017-12-29 | 2022-10-12 | 에이피 바이오사이언시스, 아이엔씨. | 암 치료법을 위한 면역 체크포인트 조절을 갖는 단일특이성 및 이중특이성 단백질 |
| US12247060B2 (en) * | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| AU2019227715B2 (en) * | 2018-02-28 | 2022-03-31 | Ap Biosciences, Inc. | Bifunctional proteins combining checkpoint blockade for targeted therapy |
| WO2019210155A1 (en) * | 2018-04-26 | 2019-10-31 | The Trustees Of The University Of Pennsylvania | Compositions and methods for retrieving tumor-related antibodies and antigens |
| EP3794034A1 (en) | 2018-05-15 | 2021-03-24 | Autolus Limited | Chimeric antigen receptor |
| BR112020024351A2 (pt) | 2018-06-01 | 2021-02-23 | Novartis Ag | moléculas de ligação contra bcma e usos das mesmas |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN112771076B (zh) | 2018-09-27 | 2024-04-02 | 奥托路斯有限公司 | 嵌合抗原受体 |
| WO2020086328A1 (en) * | 2018-10-25 | 2020-04-30 | The Medical College Of Wisconsin, Inc. | Targeting clptm1l for treatment and prevention of cancer |
| SG11202109061YA (en) | 2019-02-21 | 2021-09-29 | Marengo Therapeutics Inc | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| US20220145325A1 (en) | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| CN112300279A (zh) * | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| AU2020325315A1 (en) | 2019-08-07 | 2022-03-24 | Aqualung Therapeutics Corp. | Anti-NAMPT antibodies and uses thereof |
| EP4084823A4 (en) | 2020-01-03 | 2024-05-15 | Marengo Therapeutics, Inc. | ANTI-TCR ANTIBODY MOLECULES AND THEIR USES |
| WO2021242961A1 (en) * | 2020-05-27 | 2021-12-02 | Vanderbilt University | Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor |
| CN113801228B (zh) * | 2020-06-17 | 2023-01-17 | 常州费洛斯药业科技有限公司 | 靶向cd38的单链抗体、全人源嵌合抗原受体、制备方法和应用 |
| JP2023549780A (ja) | 2020-11-04 | 2023-11-29 | ジュノー セラピューティクス インコーポレイテッド | 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法 |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| JP2024509853A (ja) | 2021-03-03 | 2024-03-05 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法およびｄｇｋ阻害剤の組合せ |
| US20250283037A1 (en) | 2021-05-06 | 2025-09-11 | Juno Therapeutics Gmbh | Methods for stimulating and transducing t cells |
| AU2022292159A1 (en) * | 2021-06-18 | 2023-12-21 | Autolus Limited | Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseases |
| IL310434A (en) | 2021-07-29 | 2024-03-01 | Sonoma Biotherapeutics Inc | A chimeric extracellular matrix-specific antigen receptor from a destroyer to target regulatory T cells for the treatment of autoimmune diseases |
| WO2023200873A2 (en) * | 2022-04-12 | 2023-10-19 | Washington University | Chimeric antigen receptor compositions and methods of using the same |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| IL316839A (en) | 2022-05-17 | 2025-01-01 | Umoja Biopharma Inc | Production of viral particles |
| JP2025524373A (ja) | 2022-06-10 | 2025-07-30 | ウモジャ バイオファーマ インコーポレイテッド | 操作された幹細胞およびその使用 |
| CN120051297A (zh) | 2022-06-30 | 2025-05-27 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法 |
| KR20250048566A (ko) * | 2022-08-08 | 2025-04-09 | 일라이 릴리 앤드 캄파니 | 트랜스페린 수용체 결합 단백질 및 접합체 |
| CN120152717A (zh) | 2022-09-08 | 2025-06-13 | 朱诺治疗学股份有限公司 | T细胞疗法和连续或间歇dgk抑制剂给药的组合 |
| WO2024097992A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
| EP4615960A1 (en) | 2022-11-09 | 2025-09-17 | C3S2 GmbH | Methods for manufacturing engineered immune cells |
| WO2024102948A1 (en) * | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| JP2026504491A (ja) | 2023-02-03 | 2026-02-05 | ツェー３エス２ ゲーエムベーハー | 操作された免疫細胞の非ウイルス的製造のための方法 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025096878A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics, Inc. | Rna for in vivo transfection with increased expression |
| WO2025129084A1 (en) | 2023-12-13 | 2025-06-19 | Umoja Biopharma, Inc. | Engineered induced stem cell derived myeloid cells and methods of differentiating and using same |
| US20250332281A2 (en) | 2023-12-15 | 2025-10-30 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025231174A1 (en) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2025235604A1 (en) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Fusion protein for use as immune cell engager |
| WO2026025092A1 (en) | 2024-07-26 | 2026-01-29 | Juno Therapeutics, Inc. | Synthetic promoters for t cell expression |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1975A (en) | 1841-02-12 | Manner of constructing corn-shellers | ||
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| CA2169950A1 (en) | 1993-09-03 | 1995-03-09 | Naoshi Fukushima | Monoclonal antibody that induces apoptosis |
| WO2001027613A2 (de) | 1999-10-12 | 2001-04-19 | Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh | Verbessertes verfahren zum nachweis von säure-resistenten mikroorganismen im stuhl |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| KR20120053525A (ko) | 2000-06-16 | 2012-05-25 | 캠브리지 안티바디 테크놀로지 리미티드 | 면역특이적으로 ＢＬｙＳ에 결합하는 항체 |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| BRPI0516284A (pt) | 2004-09-23 | 2008-09-02 | Genentech Inc | anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto |
| WO2006039238A2 (en) | 2004-09-30 | 2006-04-13 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Irta2 antibodies and methods of use |
| CA2594318A1 (en) | 2005-01-12 | 2006-07-20 | Medarex, Inc. | Irta-2 antibodies and their uses |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| EP2065398A1 (en) | 2007-11-29 | 2009-06-03 | Cytos Biotechnology AG | Human monoclonal nicotine specific antibodies |
| SG174992A1 (en) | 2009-04-01 | 2011-11-28 | Genentech Inc | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| SG174930A1 (en) | 2009-04-01 | 2011-11-28 | Genentech Inc | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| HRP20190556T1 (hr) | 2009-11-03 | 2019-06-14 | City Of Hope | SKRAĆENI OBLIK RECEPTORA EPIDERMALNOG FAKTORA RASTA ZA (EGFRt) ODABIR TRANSDUCIRANIH T-STANICA |
| US20130280220A1 (en) * | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| SI2961831T1 (sl) * | 2013-02-26 | 2020-10-30 | Memorial Sloan Kettering Cancer Center | Sestavki in postopki za imunoterapijo |
| ES2645393T3 (es) * | 2013-05-29 | 2017-12-05 | Cellectis | Métodos de manipulación de linfocitos T para inmunoterapia usando el sistema de nucleasa Cas guiada por ARN |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| WO2015142675A2 (en) * | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| CA2969870A1 (en) * | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| CN109072199B (zh) | 2014-12-05 | 2022-10-28 | 纪念斯隆-凯特琳癌症中心 | 靶向Fc受体样5的嵌合抗原受体及其用途 |
| MY197441A (en) * | 2015-12-04 | 2023-06-19 | Memorial Sloan Kettering Cancer Center | Antibodies targeting fc receptor-like 5 and method of use |
-
2015
- 2015-12-04 CN CN201580075562.5A patent/CN109072199B/zh active Active
- 2015-12-04 AU AU2015357543A patent/AU2015357543B2/en active Active
- 2015-12-04 EP EP24206281.8A patent/EP4506036A3/en active Pending
- 2015-12-04 KR KR1020177018388A patent/KR20170108946A/ko not_active Ceased
- 2015-12-04 EP EP15864773.5A patent/EP3227436B1/en active Active
- 2015-12-04 MY MYPI2017000852A patent/MY192062A/en unknown
- 2015-12-04 BR BR112017011936A patent/BR112017011936A8/pt not_active IP Right Cessation
- 2015-12-04 MX MX2017007249A patent/MX395028B/es unknown
- 2015-12-04 WO PCT/US2015/064134 patent/WO2016090337A1/en not_active Ceased
- 2015-12-04 SG SG10202008076RA patent/SG10202008076RA/en unknown
- 2015-12-04 CN CN202211233565.5A patent/CN116063565A/zh active Pending
- 2015-12-04 SG SG11201704550XA patent/SG11201704550XA/en unknown
- 2015-12-04 NZ NZ732570A patent/NZ732570A/en not_active IP Right Cessation
- 2015-12-04 JP JP2017529750A patent/JP7174522B2/ja active Active
-
2017
- 2017-06-04 IL IL252655A patent/IL252655B/en unknown
- 2017-06-05 US US15/614,108 patent/US11059891B2/en active Active
- 2017-06-05 PH PH12017501041A patent/PH12017501041A1/en unknown
-
2021
- 2021-05-27 US US17/332,853 patent/US12139538B2/en active Active
- 2021-11-04 IL IL287835A patent/IL287835A/en unknown
-
2022
- 2022-01-20 AU AU2022200381A patent/AU2022200381A1/en not_active Abandoned
- 2022-02-28 JP JP2022029515A patent/JP2022066290A/ja not_active Withdrawn
-
2024
- 2024-02-13 JP JP2024019513A patent/JP2024040376A/ja active Pending
- 2024-10-08 US US18/909,536 patent/US20250059283A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504094A5 (Direct) | ||
| JP2017537925A5 (Direct) | ||
| JP2017537629A5 (Direct) | ||
| RU2017123548A (ru) | Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток, и их применение | |
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| JP2022116230A (ja) | 免疫療法用改変細胞 | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2022066290A5 (Direct) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2015527070A5 (Direct) | ||
| JP2020517295A5 (Direct) | ||
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2016520074A5 (Direct) | ||
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| JP2019521645A5 (Direct) | ||
| HRP20241057T1 (hr) | Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe | |
| IL275391B2 (en) | Antibodies binding ctla-4 and uses thereof | |
| CN113603788A (zh) | 免疫调节剂 | |
| JP2017524367A5 (Direct) | ||
| IT201800003464A1 (it) | Cellule T CAR-CD30 per il trattamento di tumori CD30+ | |
| JP2020512973A5 (Direct) | ||
| JP2018500337A5 (Direct) | ||
| CN111971059A (zh) | 使用过继细胞疗法和检查点抑制剂的组合疗法 | |
| IL297916A (en) | Compositions and methods for tcr reprogramming using CD70-specific fusion proteins | |
| EP4271484A1 (en) | Antibodies to tnfr2 and uses thereof |